Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17653795 | 0.95 | ABCB1 (0.76) | ABCB1ABCG2 | |
| SCHEMBL4040317 | 0.92 | ABCB1 (0.82) | ABCB1ABCG2 | |
| SCHEMBL7173150 | 0.91 | ABCG2 (0.80) | ABCB1ABCG2 | |
| SCHEMBL4040133 | 0.91 | ABCB1 (0.80) | ABCB1ABCG2 | |
| SCHEMBL7168625 | 0.91 | ABCB1 (0.80) | ABCB1ABCG2 | |
| SCHEMBL4048100 | 0.91 | ABCB1 (0.80) | ABCB1ABCG2 | |
| SCHEMBL3885917 | 0.91 | ABCB1 (1.00) | ABCB1ABCG2 | |
| SCHEMBL3885147 | 0.90 | ABCB1 (0.77) | ABCB1ABCG2 | |
| SCHEMBL4041965 | 0.90 | ABCB1 (0.76) | ABCB1ABCG2 | |
| SCHEMBL4045322 | 0.90 | ABCB1 (0.79) | ABCB1ABCG2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7524861-B2 | Process for the preparation of a hydrate of an anthranilic acid derivative | XENOVA LIMITED (GB) | 2009-04-28 | — | — | US | claimed |
| EP-1506188-B1 | PROCESS FOR THE PREPARATION OF A HYDRATE OF AN ANTHRANILIC ACID DERIVATIVE | XENOVA LTD (GB) | 2009-02-25 | — | — | EP | claimed |
| US-20050222199-A1 | Process for the preparation of a hydrate of an antranilic acid derivative | XENOVA LIMITED (GB) | 2005-10-06 | — | — | US | claimed |
| EP-1506188-A1 | PROCESS FOR THE PREPARATION OF A HYDRATE OF AN ANTHRANILIC ACID DERIVATIVE | Xenova Limited (GB) | 2005-02-16 | — | — | EP | claimed |
| EP-0934276-B1 | ANTHRANILIC ACID DERIVATIVES AS MULTI DRUG RESISTANCE MODULATORS | XENOVA LTD (GB) | 2003-12-17 | — | — | EP | claimed |
| WO-2003095447-A1 | PROCESS FOR THE PREPARATION OF A HYDRATE OF AN ANTHRANILIC ACID DERIVATIVE | XENOVA LIMITED (GB) | 2003-11-20 | — | — | WO | claimed |
| US-6218393-B1 | IN THERAPY OF MULTIDRUG RESISTANT CANCERS, FOR EXAMPLE TO POTENTIATE CYTOTOXICITY OF CANCER DRUG | XENOVA LIMITED (GB) | 2001-04-17 | — | — | US | claimed |
| US-20190343827-A1 | DEUTERATED ANALOGS OF TARIQUIDAR | IZUMI TECHNOLOGY, LLC (US) | 2019-11-14 | — | — | US | disclosed |
| US-20190343827-A1 | DEUTERATED ANALOGS OF TARIQUIDAR | IZUMI TECHNOLOGY, LLC (US) | 2019-11-14 | — | — | US | disclosed |
| US-7524861-B2 | Process for the preparation of a hydrate of an anthranilic acid derivative | XENOVA LIMITED (GB) | 2009-04-28 | — | — | US | disclosed |
| EP-1506188-B1 | PROCESS FOR THE PREPARATION OF A HYDRATE OF AN ANTHRANILIC ACID DERIVATIVE | XENOVA LTD (GB) | 2009-02-25 | — | — | EP | disclosed |
| EP-1711490-A4 | NOVEL P-GLYCOPROTEIN INHIBITOR, METHOD FOR THE PREPARATION THEREOF AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME | HANMI PHARM IND CO LTD (KR) | 2007-04-04 | — | — | EP | disclosed |
| EP-1711490-A1 | NOVEL P-GLYCOPROTEIN INHIBITOR, METHOD FOR THE PREPARATION THEREOF AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME | Hanmi Pharm. Co., Ltd. (KR) | 2006-10-18 | — | — | EP | disclosed |
| US-20050222199-A1 | Process for the preparation of a hydrate of an antranilic acid derivative | XENOVA LIMITED (GB) | 2005-10-06 | — | — | US | disclosed |
| WO-2005033101-A1 | NOVEL P-GLYCOPROTEIN INHIBITOR, METHOD FOR THE PREPARATION THEREOF AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME | HANMI PHARM. CO., LTD. (KR) | 2005-04-14 | — | — | WO | disclosed |
| EP-1506188-A1 | PROCESS FOR THE PREPARATION OF A HYDRATE OF AN ANTHRANILIC ACID DERIVATIVE | Xenova Limited (GB) | 2005-02-16 | — | — | EP | disclosed |
| WO-2003095447-A1 | PROCESS FOR THE PREPARATION OF A HYDRATE OF AN ANTHRANILIC ACID DERIVATIVE | XENOVA LIMITED (GB) | 2003-11-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190343827-A1 | DEUTERATED ANALOGS OF TARIQUIDAR | ABCG2, ABCB11, ALPP | ABCB1 4/4885ABCG2 1/4885 |
| US-20050222199-A1 | Process for the preparation of a hydrate of an antranilic acid derivative | H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, FHIT, ATIC | ABCB1 647/4885ABCG2 8/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.